Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed University of Wisconsin, Madison National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic breast cancer that has not responded to previous chemotherapy.

Timeline

Start: 1998-05
Primary completion: 1998-05
Completion: 1998-05

Outcome

Missed primary endpoint

paper One-year FFP rate was zero. PMID 17885756 ↗

Publications

Results Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. doi: 10.1007/s00280-007-0585-6. Epub 2007 Sep 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	perillyl alcohol	Small molecule	1200 mg/m2	Oral
Subject	perillyl alcohol	Small molecule	1500 mg/m2	Oral